Viking Therapeutics (VKTX)
Market Price (2/4/2026): $29.42 | Market Cap: $3.3 BilSector: Health Care | Industry: Biotechnology
Viking Therapeutics (VKTX)
Market Price (2/4/2026): $29.42Market Cap: $3.3 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% | Weak multi-year price returns2Y Excs Rtn is -17% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Obesity Treatment, and NASH Treatment. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -275 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% | ||
| Key risksVKTX key risks include [1] potential clinical trial setbacks for its lead candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Obesity Treatment, and NASH Treatment. |
| Weak multi-year price returns2Y Excs Rtn is -17% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -275 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% |
| Key risksVKTX key risks include [1] potential clinical trial setbacks for its lead candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Viking Therapeutics (VKTX) stock has lost about 25% since 10/31/2025 because of the following key factors:
1. Continued Impact of Disappointing Oral VK2735 Phase 2 Results.While reported in August 2025, the market continued to react to the disappointing Phase 2 results for Viking's oral obesity pill, VK2735. The trial indicated up to 12.2% weight loss, but a 20% discontinuation rate due to gastrointestinal adverse events raised concerns about safety and tolerability among investors. This initial setback contributed to a 42% stock drop in August 2025, and negative sentiment stemming from these results likely continued to weigh on the stock into early 2026.
2. Intensifying Competition and Pricing Pressure in the Obesity Market.The obesity drug market became increasingly competitive during this period. Novo Nordisk launched its oral Wegovy pill in January 2026, and an FDA decision for Eli Lilly's oral obesity pill is expected in the first half of 2026, increasing pressure on Viking Therapeutics' pipeline. Additionally, new federal healthcare policies implemented as of January 2026 have led to reduced monthly costs for obesity drugs, potentially narrowing profit margins for new entrants like Viking. AstraZeneca also announced a new collaboration on February 2, 2026, to develop next-generation obesity therapies, further escalating the competitive landscape.
Show more
1. Continued Impact of Disappointing Oral VK2735 Phase 2 Results.While reported in August 2025, the market continued to react to the disappointing Phase 2 results for Viking's oral obesity pill, VK2735. The trial indicated up to 12.2% weight loss, but a 20% discontinuation rate due to gastrointestinal adverse events raised concerns about safety and tolerability among investors. This initial setback contributed to a 42% stock drop in August 2025, and negative sentiment stemming from these results likely continued to weigh on the stock into early 2026.
2. Intensifying Competition and Pricing Pressure in the Obesity Market.The obesity drug market became increasingly competitive during this period. Novo Nordisk launched its oral Wegovy pill in January 2026, and an FDA decision for Eli Lilly's oral obesity pill is expected in the first half of 2026, increasing pressure on Viking Therapeutics' pipeline. Additionally, new federal healthcare policies implemented as of January 2026 have led to reduced monthly costs for obesity drugs, potentially narrowing profit margins for new entrants like Viking. AstraZeneca also announced a new collaboration on February 2, 2026, to develop next-generation obesity therapies, further escalating the competitive landscape.
Show more
Stock Movement Drivers
Fundamental Drivers
The -22.8% change in VKTX stock from 10/31/2025 to 2/3/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 38.08 | 29.41 | -22.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 112 | 112 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| VKTX | -22.8% | |
| Market (SPY) | 1.1% | 25.0% |
| Sector (XLV) | 6.8% | 31.3% |
Fundamental Drivers
The -9.7% change in VKTX stock from 7/31/2025 to 2/3/2026 was primarily driven by a -0.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 32.57 | 29.41 | -9.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 112 | 112 | -0.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| VKTX | -9.7% | |
| Market (SPY) | 9.4% | 21.4% |
| Sector (XLV) | 18.7% | 14.3% |
Fundamental Drivers
The -10.2% change in VKTX stock from 1/31/2025 to 2/3/2026 was primarily driven by a -1.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 32.75 | 29.41 | -10.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 111 | 112 | -1.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| VKTX | -10.2% | |
| Market (SPY) | 15.6% | 33.9% |
| Sector (XLV) | 6.3% | 28.7% |
Fundamental Drivers
The 235.7% change in VKTX stock from 1/31/2023 to 2/3/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.76 | 29.41 | 235.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 77 | 112 | -31.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/3/2026| Return | Correlation | |
|---|---|---|
| VKTX | 235.7% | |
| Market (SPY) | 75.9% | 19.6% |
| Sector (XLV) | 20.9% | 15.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VKTX Return | -18% | 104% | 98% | 116% | -13% | -15% | 431% |
| Peers Return | 18% | 73% | -4% | 4% | 22% | 10% | 176% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| VKTX Win Rate | 42% | 42% | 50% | 50% | 25% | 50% | |
| Peers Win Rate | 48% | 53% | 38% | 48% | 52% | 70% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| VKTX Max Drawdown | -18% | -54% | -14% | -7% | -50% | -17% | |
| Peers Max Drawdown | -16% | -27% | -45% | -19% | -21% | -5% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LLY, MDGL, AMGN, PFE, ALT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/3/2026 (YTD)
How Low Can It Go
| Event | VKTX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -78.2% | -25.4% |
| % Gain to Breakeven | 358.3% | 34.1% |
| Time to Breakeven | 236 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -57.0% | -33.9% |
| % Gain to Breakeven | 132.5% | 51.3% |
| Time to Breakeven | 99 days | 148 days |
| 2018 Correction | ||
| % Loss | -67.6% | -19.8% |
| % Gain to Breakeven | 208.2% | 24.7% |
| Time to Breakeven | 1,287 days | 120 days |
Compare to LLY, MDGL, AMGN, PFE, ALT
In The Past
Viking Therapeutics's stock fell -78.2% during the 2022 Inflation Shock from a high on 2/5/2021. A -78.2% loss requires a 358.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Viking Therapeutics (VKTX)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
AI Analysis | Feedback
Here are 1-2 brief analogies for Viking Therapeutics (VKTX):
- An emerging Eli Lilly or Novo Nordisk for next-generation weight loss and metabolic drugs.
- A biotech challenger in the obesity and metabolic disease drug market, aiming to rival pharmaceutical giants.
AI Analysis | Feedback
- VK2809 (razafemazole): A liver-selective thyroid hormone receptor beta (TRβ) agonist in clinical development for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and dyslipidemia.
- VK2735: A dual GLP-1/GIP receptor agonist currently in clinical development for the treatment of obesity and other metabolic disorders.
- VK0214: A novel, orally available small molecule thyroid hormone receptor beta (TRβ) agonist being developed for the treatment of X-linked adrenoleukodystrophy (X-ALD).
AI Analysis | Feedback
Viking Therapeutics (symbol: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for metabolic and endocrine disorders. As such, the company does not currently have any commercialized products on the market from which it generates sales revenue.
Therefore, Viking Therapeutics does not have "major customers" in the traditional sense of companies or individuals purchasing its products or services. Its primary activities involve research and development, preclinical studies, and clinical trials for its drug candidates.
The company's operations are primarily funded through financing activities, such as equity offerings, and potentially grants or strategic collaborations, rather than the sale of commercialized pharmaceutical products.
AI Analysis | Feedback
nullAI Analysis | Feedback
Brian Lian, Ph.D. President and Chief Executive Officer Dr. Lian co-founded Viking Therapeutics in September 2012 and has served as President and Chief Executive Officer and a director since the company's inception. Prior to founding Viking, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey from 2012 to 2013, where he covered small and mid-cap biotechnology companies with a focus on diabetes, oncology, infectious disease, and neurology. He also held similar roles as Managing Director and Senior Research Analyst at Global Hunter Securities (2011-2012) and Executive Director and Senior Biotechnology Analyst at CIBC World Markets (2006-2008). Before his career in equity research, Dr. Lian was a research scientist in small molecule drug discovery at Amgen and Microcide Pharmaceuticals. He holds an MBA in accounting and finance from Indiana University and M.S. and Ph.D. degrees in organic chemistry from The University of Michigan. Greg Zante Chief Financial Officer Mr. Zante was appointed Chief Financial Officer in January 2021. He joined Viking in 2016 as Vice President of Finance and Operations and most recently served as the company's Senior Vice President of Finance. Mr. Zante has nearly 25 years of financial management experience in both public and private biotechnology and accounting firms. Before joining Viking, he served as Chief Financial Officer at Dance Biopharm, a biopharmaceutical company focused on diabetes, where he managed private financing and prepared the company for initial public offering activities. His previous senior positions include roles at Sangamo Therapeutics, Calyx Therapeutics, and Matrix Pharmaceuticals. He is a Certified Public Accountant in California and previously worked as a senior staff accountant at Ernst & Young. Marianne Mancini Chief Operating Officer Ms. Mancini was appointed Chief Operating Officer in January 2021. She brings over 30 years of experience in the pharmaceutical and biotechnology industry, specializing in the management and oversight of clinical trials from early to late-stage drug development. Ms. Mancini joined Viking in 2015 as Vice President of Clinical Operations. Prior to Viking, she held positions as Senior Director of Clinical Operations at Ambit Biosciences Corporation and Aires Pharmaceuticals, Inc. She also served as Senior Director of Project Management and Clinical Operations at Arena Pharmaceuticals, Inc., where she was the project team leader for the company's obesity compound, BELVIQ®. Michael Morneau Vice President, Finance and Administration Mr. Morneau serves as Vice President of Finance and Administration. He has over 20 years of accounting and financial experience in public and private companies within the biotechnology and accounting industries. Before joining Viking, he was Vice President of Finance and Chief Accounting Officer at Trius Therapeutics, Inc., which became a subsidiary of Cubist Pharmaceuticals, Inc. following Cubist's acquisition of Trius. Prior to Trius, he was Director of Lilly Research Labs Finance at Eli Lilly and Company. Earlier in his career, he was Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company that was acquired by Eli Lilly. He also served as Controller at Momenta Pharmaceuticals, Inc. Hiroko Masamune, Ph.D. Chief Development Officer Dr. Masamune serves as Viking's Chief Development Officer and has over 25 years of pharmaceutical development experience. Before joining Viking, she was Vice President, Product Development at Aires Pharmaceuticals, Inc., a company focused on therapies for pulmonary vascular disorders. Prior to Aires, she was Vice President, Product Development at Palkion Inc., where she was responsible for all aspects of preclinical development and served as alliance manager. Dr. Masamune also served as Senior Director, Pharmaceutical Sciences at Neurogen Corp., overseeing various clinical candidates. She spent 14 years in drug discovery and development at Pfizer, working in cardiovascular, pulmonary, and infectious diseases.AI Analysis | Feedback
The key risks to Viking Therapeutics (VKTX) are:
- Clinical Development Risks and Binary Outcomes: As a clinical-stage biopharmaceutical company, Viking Therapeutics' future is heavily reliant on the successful development, positive clinical trial results, and regulatory approval of its drug candidates. Disappointing clinical trial outcomes, such as the tolerability issues and a 28% discontinuation rate observed in the Phase 2 results for its experimental oral obesity pill VK2735, can significantly impact the company's stock price and commercial prospects. The success of its lead candidates, particularly the Phase 3 trials for VK2735, represents critical milestones, and any setbacks could lead to substantial losses.
- Intense Competition and Market Saturation: Viking Therapeutics operates in highly competitive therapeutic areas, particularly in the metabolic disorder and obesity markets. This landscape is dominated by large pharmaceutical companies such as Eli Lilly and Novo Nordisk, which possess established drugs, extensive pipelines, and robust commercial infrastructures. Viking faces significant challenges in differentiating its products and gaining market share against these entrenched players, with the potential for a crowded GLP-1 market further intensifying competitive pressures.
- Financial Risks and Dilution: Viking Therapeutics is a pre-revenue company and consistently reports net losses due to substantial research and development (R&D) expenses. Advancing drug candidates through late-stage clinical trials, especially costly Phase 3 programs, requires significant capital investment. While the company currently maintains a strong cash position, there is an ongoing risk that future capital requirements could lead to additional equity financing and subsequent dilution for existing shareholders.
AI Analysis | Feedback
Eli Lilly's retatrutide (triple GLP-1, GIP, and glucagon receptor agonist) represents a clear emerging threat to Viking Therapeutics' VK2735 (dual GLP-1 and GIP receptor agonist) in the highly competitive obesity market. Retatrutide is currently in Phase 3 clinical development and has demonstrated significant weight loss in earlier trials, potentially setting a higher efficacy benchmark than dual agonists, including VK2735. As a triple agonist, it targets additional pathways that may offer superior outcomes. Its advanced stage of development and strong clinical profile position it as a formidable competitor that could establish a new standard of care before VK2735 even reaches market approval, thereby limiting VKTX's potential market share, pricing power, and commercial viability for its key obesity asset.
AI Analysis | Feedback
Viking Therapeutics (VKTX) is developing several promising product candidates targeting significant addressable markets:
VK2735 (Dual GLP-1/GIP Agonist) for Obesity and Metabolic Disorders
- The global obesity treatment market was valued at USD 15.92 billion in 2024 and is projected to reach USD 60.53 billion by 2030, growing at a compound annual growth rate (CAGR) of 22.31% from 2025 to 2030.
- Another estimate places the global anti-obesity medication (AOM) market at approximately US$130 billion between 2024 and 2034.
- The overall weight-loss therapeutics market is valued at around $150 billion.
- North America is a dominant region in the obesity treatment market, holding a 73.39% revenue share in 2024.
VK2809 (TRβ Agonist) for NASH, NAFLD, and Elevated LDL-C
- The global Nonalcoholic Steatohepatitis (NASH) market size is estimated at USD 9.98 billion in 2024 and is expected to reach USD 314.07 billion by 2033, demonstrating a substantial CAGR of 46.7%.
- Other projections indicate the global NASH market could reach $57.5 billion by 2033 with a CAGR of 27.9%, or increase from USD 7.75 billion in 2024 to USD 92.5 billion by 2034 with a CAGR of 28.14%.
- North America held a dominant 79% share of the global non-alcoholic steatohepatitis (NASH) treatment market in 2024.
- The global non-alcoholic fatty liver disease (NAFLD) drug market size is calculated at USD 21.98 billion in 2025 and is forecasted to reach approximately USD 33.6 billion by 2034.
VK0214 (TRβ Agonist) for X-linked Adrenoleukodystrophy (X-ALD)
- The global X-Linked Adrenoleukodystrophy market is projected to grow from USD 0.82 billion in 2024 to USD 1.48 billion by 2035, at a CAGR of 5.49% from 2025 to 2035.
AI Analysis | Feedback
Viking Therapeutics (VKTX), a clinical-stage biopharmaceutical company, does not currently generate revenue from product sales. Therefore, its future revenue growth over the next 2-3 years is entirely dependent on the successful progression, approval, and commercialization of its pipeline candidates. Key drivers of potential future revenue growth include:- Advancement and Potential Approval of VK2735 (Subcutaneous Formulation) for Obesity: VK2735 is Viking's leading obesity drug candidate, a dual GLP-1/GIP receptor agonist, which has demonstrated significant efficacy in Phase 2 clinical trials. The company is accelerating its development by moving directly into Phase 3 trials for the subcutaneous formulation, potentially speeding up its market entry by 18-24 months. Enrollment for the pivotal VANQUISH-1 study is expected to conclude by the end of 2025, and for VANQUISH-2 by the first quarter of 2026. Analysts project potential peak sales of VK2735 to reach up to $21.6 billion, with a substantial portion from the U.S. market, if it gains regulatory approval. The overall weight-loss drug market is anticipated to reach $120 billion by 2030 and $150 billion by 2035.
- Development of VK2735 (Oral Formulation) for Obesity: In addition to the injectable form, Viking is also developing an oral formulation of VK2735. This oral version has shown promising weight loss results and favorable tolerability in Phase 1 and Phase 2 studies. A Phase 2 maintenance dosing study is currently in progress, with further data expected. The successful development and potential approval of an oral option could significantly expand the addressable market and offer greater dosing flexibility for patients.
- Progression of VK2809 for MASH/NASH: VK2809 is an orally administered, selective thyroid hormone receptor beta agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and fibrosis. The drug has successfully met its primary and secondary endpoints in a Phase 2b study. The company plans to engage with the FDA to discuss the next steps for this program. Analyst projections for VK2809's peak sales reach up to $4 billion, targeting a MASH/NASH market estimated to grow to $108 billion by 2030.
- Introduction of a Novel Amylin Candidate for Obesity: Viking is expanding its pipeline in obesity treatments with a novel dual amylin and calcitonin receptor agonist (DACRA). Positive preclinical data has been presented, and an Investigational New Drug (IND) submission for this candidate is anticipated in 2025 or the first quarter of 2026, marking its entry into clinical development. This represents a new product class that could contribute to future revenue if successfully developed.
AI Analysis | Feedback
Share Repurchases
- Viking Therapeutics authorized a $250.0 million share repurchase program in February 2025.
- No repurchases were made under the authorized program in Q3 2025.
- Historical data shows small quarterly buybacks, with the largest being $5.62 million in Q1 2022 and $5.41 million in Q2 2023.
Share Issuance
- A March 2024 offering resulted in $597.1 million in net proceeds for the company.
- Shares outstanding increased from approximately 78 million in Q1 2023 to 112 million in Q1 2025, indicating dilution through equity offerings.
- The number of shares outstanding increased by 5.48% in one year, reaching 113.04 million as of October 15, 2025.
Inbound Investments
- The company maintained strong liquidity, reporting $100.4 million in cash and cash equivalents and $614.2 million in short-term investments as of September 30, 2025.
- Short-term investments grew substantially from $117.3 million in Q1 2023 to $813.9 million in Q1 2025, reflecting significant capital reserves.
- Total equity significantly increased from $134 million in Q1 2023 to $847 million in Q1 2025, driven by funding raises and capital accumulation.
Capital Expenditures
- Viking Therapeutics has reported minimal or no traditional capital expenditures in recent years, with "n/a" or "-" indicated in financial statements for capital expenditures.
- The company entered into multi-year manufacturing agreements for VK2735, involving prepayments from 2025 to 2028 that will be credited against future orders.
- A lease amendment for expanded headquarters space includes a monthly base rent of $63,000, starting from April 1, 2026, or substantial completion.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 184.00 |
| Mkt Cap | 78.7 |
| Rev LTM | 18,356 |
| Op Inc LTM | 4,290 |
| FCF LTM | 3,185 |
| FCF 3Y Avg | 629 |
| CFO LTM | 6,505 |
| CFO 3Y Avg | 4,681 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.6% |
| Rev Chg 3Y Avg | -1.0% |
| Rev Chg Q | 12.4% |
| QoQ Delta Rev Chg LTM | 3.0% |
| Op Mgn LTM | 24.1% |
| Op Mgn 3Y Avg | 22.4% |
| QoQ Delta Op Mgn LTM | 2.3% |
| CFO/Rev LTM | 20.8% |
| CFO/Rev 3Y Avg | 19.6% |
| FCF/Rev LTM | 10.8% |
| FCF/Rev 3Y Avg | 7.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 78.7 |
| P/S | 14.6 |
| P/EBIT | 3.3 |
| P/E | 4.5 |
| P/CFO | 1.9 |
| Total Yield | -0.0% |
| Dividend Yield | 0.3% |
| FCF Yield 3Y Avg | -1.8% |
| D/E | 0.0 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.9% |
| 3M Rtn | 10.3% |
| 6M Rtn | 23.0% |
| 12M Rtn | 13.3% |
| 3Y Rtn | 62.2% |
| 1M Excs Rtn | -2.8% |
| 3M Excs Rtn | 13.6% |
| 6M Excs Rtn | 13.1% |
| 12M Excs Rtn | -1.2% |
| 3Y Excs Rtn | -13.2% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Development of novel first-in-class or best-in-class therapies for the treatment of metabolic and | 0 | ||||
| Total | 0 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Development of novel first-in-class or best-in-class therapies for the treatment of metabolic and | 368 | 169 | 211 | 257 | 284 |
| Total | 368 | 169 | 211 | 257 | 284 |
Price Behavior
Price Behavior
| Market Price | $29.41 | |
| Market Cap ($ Bil) | 3.3 | |
| First Trading Date | 04/29/2015 | |
| Distance from 52W High | -30.1% | |
| 50 Days | 200 Days | |
| DMA Price | $34.24 | $31.16 |
| DMA Trend | up | down |
| Distance from DMA | -14.1% | -5.6% |
| 3M | 1YR | |
| Volatility | 58.4% | 81.0% |
| Downside Capture | 215.76 | 209.43 |
| Upside Capture | 96.45 | 170.95 |
| Correlation (SPY) | 25.4% | 33.9% |
VKTX Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.08 | 0.32 | 1.25 | 1.73 | 1.42 | 1.47 |
| Up Beta | 2.14 | -0.76 | 0.87 | 1.08 | 1.35 | 1.27 |
| Down Beta | -0.12 | -0.02 | 1.07 | 1.68 | 0.98 | 1.80 |
| Up Capture | -377% | -28% | 46% | 189% | 251% | 413% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 14 | 24 | 60 | 123 | 367 |
| Down Capture | -84% | 178% | 205% | 220% | 147% | 107% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 27 | 37 | 65 | 127 | 382 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VKTX | |
|---|---|---|---|---|
| VKTX | -9.5% | 81.1% | 0.27 | - |
| Sector ETF (XLV) | 6.3% | 17.2% | 0.20 | 28.7% |
| Equity (SPY) | 15.6% | 19.2% | 0.63 | 33.9% |
| Gold (GLD) | 77.2% | 24.5% | 2.30 | 1.1% |
| Commodities (DBC) | 10.0% | 16.5% | 0.40 | 9.2% |
| Real Estate (VNQ) | 2.9% | 16.5% | -0.00 | 19.9% |
| Bitcoin (BTCUSD) | -23.4% | 40.3% | -0.56 | 25.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VKTX | |
|---|---|---|---|---|
| VKTX | 31.2% | 101.6% | 0.65 | - |
| Sector ETF (XLV) | 7.8% | 14.4% | 0.36 | 17.4% |
| Equity (SPY) | 14.5% | 17.0% | 0.68 | 20.8% |
| Gold (GLD) | 21.5% | 16.8% | 1.04 | 2.1% |
| Commodities (DBC) | 12.0% | 18.9% | 0.51 | 4.5% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 13.5% |
| Bitcoin (BTCUSD) | 20.9% | 57.5% | 0.56 | 14.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VKTX | |
|---|---|---|---|---|
| VKTX | 30.4% | 99.1% | 0.66 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 19.7% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 21.4% |
| Gold (GLD) | 15.6% | 15.5% | 0.84 | 0.9% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 8.0% |
| Real Estate (VNQ) | 5.6% | 20.8% | 0.24 | 12.0% |
| Bitcoin (BTCUSD) | 69.9% | 66.5% | 1.09 | 10.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/22/2025 | 8.0% | 12.1% | 9.1% |
| 7/23/2025 | 0.3% | 0.9% | -23.2% |
| 4/23/2025 | -0.5% | 11.9% | 7.5% |
| 2/5/2025 | -6.1% | -12.5% | -13.1% |
| 10/23/2024 | 21.2% | 18.8% | -14.5% |
| 7/24/2024 | 28.3% | 13.1% | 27.7% |
| 4/24/2024 | 5.8% | 17.5% | -5.4% |
| 2/7/2024 | 18.0% | 31.7% | 193.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 15 | 13 |
| # Negative | 8 | 8 | 10 |
| Median Positive | 8.0% | 13.1% | 11.3% |
| Median Negative | -4.7% | -8.5% | -14.6% |
| Max Positive | 28.3% | 31.7% | 193.2% |
| Max Negative | -9.4% | -14.3% | -25.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 10/23/2025 | 10-Q |
| 06/30/2025 | 07/23/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/23/2024 | 10-Q |
| 06/30/2024 | 07/24/2024 | 10-Q |
| 03/31/2024 | 04/25/2024 | 10-Q |
| 12/31/2023 | 02/07/2024 | 10-K |
| 09/30/2023 | 10/25/2023 | 10-Q |
| 06/30/2023 | 07/26/2023 | 10-Q |
| 03/31/2023 | 04/26/2023 | 10-Q |
| 12/31/2022 | 02/10/2023 | 10-K |
| 09/30/2022 | 10/26/2022 | 10-Q |
| 06/30/2022 | 07/27/2022 | 10-Q |
| 03/31/2022 | 04/27/2022 | 10-Q |
| 12/31/2021 | 02/09/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zante, Greg | Chief Financial Officer | Direct | Sell | 1052026 | 32.90 | 57,661 | 1,896,969 | 6,247,159 | Form |
| 2 | Mancini, Marianna | Chief Operating Officer | Direct | Sell | 1052026 | 32.98 | 57,661 | 1,901,405 | 13,493,280 | Form |
| 3 | Lian, Brian | President & CEO | Direct | Sell | 1052026 | 32.96 | 233,409 | 7,692,121 | 82,365,495 | Form |
| 4 | Foehr, Matthew W | Direct | Sell | 1052026 | 35.11 | 16,000 | 561,694 | 4,635,243 | Form | |
| 5 | Mancini, Marianna | Chief Operating Officer | Direct | Sell | 10282025 | 35.00 | 6,185 | 216,492 | 13,387,378 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.